Leishmaniasis is a tropical disease caused by aprotozoan which is obligate intracellular parasite belongs to the genus Leishmania. There are 3 forms of the disease: visceral leishmaniasis, cutaneous leishmaniasis which is the most common, and mucocutaneous leishmaniasis. The most important compounds used to treat leishmaniasis were meglumine antimoniate (e.g. glucantime), sodium stibogluconate (e.g. pentostam) and pentavalent antimonials. There are other drugs that may be used such as pentamidine and amphotericin B. Until now, the pentavalent antimonial compounds remain the corner stone in the treatment of cutaneous leishmaniasis although this group possesses high degree of toxicity. Other treatment options include the pentamidines and liposomal amphotericin B (AmBisome). Combination therapies using AmBisome and miltefosine are another effective alternative to antimonial compounds. Other latest therapeutic options include photodynamic therapy, tamoxifen and imiquimod. The proper choice of antileishmanial therapy depends on the geographic location, host immune status, availability of the drug, and expertise of the treating physician. The present review summarizes the current treatment options available for cutaneous leishmaniasis as well as some drugs on the horizon that show promising results in the treatment of cutaneous leishmaniasis.
INTRODUCTION

LABORATORY DIAGNOSIS OF CUTANEOUS LEISHMANIASIS
Diagnosis of cutaneous leishmaniasis depends on the clinical symptoms and laboratory investigations. A lot of diagnostic methods were described with a large range of variation in the specificity and sensitivity including direct parasitological examination (microscopy, histopathology, and parasite culture) and indirect testing using serology and molecular diagnostics [4] .
Direct microscopy and histopathology
The corner stone in diagnosis of leishmaniasis is parasitologic identification through histopathological examination of parasite fixed from suspected lesions and/or in vitro culture. is the press-imprint-smear (PIS). According to a recent study that compared PIS with histopathology, PIS was positive in 85.3 % of cases while histopathology was only positive in 44 % of cases. Accordingly, PIS is a sensitive and rapid method for the diagnosis of cutaneous leishmaniasis [5] .
Immunologic methods
Serologic tests for cutaneous leishmaniasis diagnosis depend on detection of the specific immune response against the parasite. Multiple immunologic tests are currently in use including indirect fluorescent antibody assay, enzyme-linked immunosorbent assay (ELISA), western blot, lateral flow assay or direct agglutination test. Unfortunately, these methods are relatively of limited value for the diagnosis of cutaneous leishmaniasis because of the poor humoral immune response of the host tissue to the infection and consequently the low sensitivity [4, 6] .
Leishmanin skin test
The Leishmanin skin test (LST, or Montenegro skin test "MST") is a good marker for cellular immune response, so it [9] . it has been reported that the LST is more sensitive in persons with old cutaneous leishmaniasis [10] [11] .
Nucleic acid amplification methods
A lot of molecular tests which are diagnostic were developed to help the diagnosis of cutaneous leishmaniasis, as these are more sensitive and specific than traditional diagnostic methods and they also use for diagnosis less invasive sampling [12] [13] . Over the past years, a lot of Polymerase Chain Reactions (PCR) targeting different gene sequences were developed, with the ribosomal DNA internal transcribed spacer 1 sequence [14] [15] [16] , or sequences within the kinetoplast DNA of Leishmania genus as the main targets [17] [18] . In disease-endemic countries, PCR needs infrastructure and technically skilled operators which make these tests less suitable for resource-restricted laboratories. Recently isothermal diagnostic platforms have been designed to polarize the parasite RNA through a potentially isothermal reaction to leishmaniasis [19] . At the same time, as the chromatographic analysis of the post-inflation analysis resulting from the use of complex equipment, maintenance is carried out on the appropriate diagnostic characteristics [20] [21] . It is essential for rapid diagnosis at the lowest cost of Leishmania discovery that non-invasive sampling is done. However, a significant difference in the clinical delicacy of molecular diagnostic s for cutaneous leishmaniasis, relying on the DNA retrieval process, the molecular testing, and sample origin [22] .
Species determination
As in most parasitic diseases, the challenge stays in having the competence to perform a rapid diagnosis of the disease and precise characterization of the genotyping of different 
LEISHMANIASIS TREATMENT
Most cases of cutaneous leishmaniasis heal without treatment and require no specific therapy, however, treatment is required in large and/or persistent lesions (Table 1) [25] .
Other drugs that can be used in the treatment plan include amphotericin B and pentamidine [25] [26] . In addition, effective vaccines for the treatment of leishmaniasis have not yet been available although trials are ongoing [27] [28] . Recently, few alternative drugs have emerged for the treatment of leishmaniasis (Table 2 ). However, none of these medications has proved satisfactory, and a few of the touted agents have been assessed adequately in clinical trials. The limited efficacy is associated with wide margin of toxicity which is further augmented by the long duration of treatment that impacts the patient's compliance [29] [30] . The structure of some importany antileishmanial drugs is shown in 
New treatment guidelines
Recently, several European guidelines have been proposed for a new treatment approach of cutaneous leishmaniasis [31] with the help of molecular techniques available for species identification this approach is made possible [32] .
Globally, the overall geographic area experience has been able to devise initial treatment, as approaches of the Old tions that were based on the efficacy and practical manners [32] . This analysis reached a 50% lost to follow-up studies of cutaneous leishmaniasis and the authors found that 37% of the analyses were dependent only on observational studies. [36] . Amphotericin administration is limited by infusion-related toxicity. This is thought to result from innate immune production of proinflammatory cytokines [37] . The amphipathic nature of amphotericin B along with its low solubility and poor permeability has posed major barriers for oral administration due to its low bioavailability. However, a new lipid-associated formulation, liposomal amphotericin B
(commonly known as "AmBisome") has been introduced to the original amphotericin B to avoid these drawbacks. This new formulation has better bioavailability, less infusion toxicity and less nephrotoxicity than the original amphotericin B (Fig 3) . It is used intravenously 3-10 mg/kg/day for 5-7
days. The lower dosage and shorter duration regimen has the same effect of the higher dosages and longer duration of treatment [38] . and 22% more had a partial remission (60-90% reduction).
Although pentavalent antimonials are frequently injected intralesionally, this study describes a similar method using amphotericin B which one might think would be very sclerotic/reactogenic based on the phlebitis that it may cause. more severe in women and young children. The overall effects are quite mild and well-tolerated [42] [43] . amazonensis as shown in a study in which edelfosine and perifosine were given to BALB/c mice in oral doses of 1 and 2.5 mg/kg/day during 28 days and 5 mg/kg/ day during 14 days, starting at two weeks after the first treatment scheme [45] . An assay comparing miltefosine at the standard dose of 20 mg/kg/day during 28 days to in vivo treatment with perifosine at a dose of 5 mg/kg/day for 14 days demonstrated higher in vivo activity of perifosine than miltefosine against L. amazonensis [44] . These findings show promise for a new treatment group in cutaneous leishmaniasis caused by L. amazonensis. Another drug, sitamaquine (WR 6026), an 8-aminoquinoline has also shown promise as an effective oral agent in a dose of 1 mg/kg/day for 2 weeks for visceral leishmaniasis [46] .
Pentamidine structural analogs
Intralesional pentavalent antimonials (ILPA) are an alternative to systemic pentavalent antimonials (SPA). In a recent study aimed to compare the cost of ILPA and SPA, and to estimate the health and economic impacts of changing the first-line treatment for cutaneous leishmaniasis in a Bolivian endemic area, the authors concluded that treating cutaneous leishmaniasis using ILPA was associated with a cost-saving and allowed two-and-a-half times the current number of patients to be treated [47] .
Imiquimod
Imiquimod is a patient-applied cream that acts as an immune response modifier and is licensed for treatment of genital warts, superficial basal cell carcinoma, and actinic keratosis [48] . Imiquimod has been recently used topically for treatment of resistant cutaneous leishmaniasis in a cream form [49] . The drug acts by stimulation of the innate immune system by activating toll-like receptor 7 (TLR7), commonly involved in pathogen recognition. Cells activated by imiquimod via TLR-7 secrete cytokines primarily interferon-α, interleukin-6, and tumor necrosis factor-α [50] . There is evidence that when imiquimod applied topically to skin, can lead to the activation of Langerhans cells, which subsequently migrate to local lymph nodes and activate the adaptive immune response [48, 51] .
Tamoxifen
This is a selective estrogen receptor modulator that has been Cutaneous leishmaniasis: treatment options and possibilities for drug repurposing as cutaneous leishmaniasis [55] . A proof-of-concept study of 31 patients self-administering daylight-activated PDT in cutaneous leishmaniasis (L. major and L. tropica) showed healing in 70% 67. After curettage of the crust over lesions, a thick layer of the photosensitizer aminolevulinate was applied to the lesions weekly, covered with a dressing and foil for 30 min, then the dressing removed, and the patient was asked to expose the area to daylight for 2.5 h. In those patients with multiple lesions, a control lesion was not initially treated and none of these healed spontaneously during the 8-10 weeks treatment session [56] .
Combination treatments
Monotherapy to yield at least additive effects at low doses of both drugs [52] . The study was repeated with combination of tamoxifen and miltefosine with similar results [53] . Additionally, combined treatment of miltefosine and paromomycin has shown to delay the onset of drug resistance in rodents infected with L. infantum [59] . In another study in Peru, they compared the use of imiquimod alone and using it with parenteral meglumine antimoniate for treatment of cutaneous leishmani-asis. In seven patients who treated with topical imiquimod cream (7.5%) with intravenous meglumine antimoniate (20 mg/kg/day) for 20 days showed a cure rate of 100%. By comparing these results with seven patients receiving parenteral meglumine antimoniate alone the result was 57% [60] . These results proved that the effect of the combined therapy in initial treatment of cutaneous leishmaniasis was better.
Conclusion
Leishmaniasis is a disease caused by an intracellular protozoan parasite transmitted by the bite of a female phlebotomine sandfly. The clinical spectrum of leishmaniasis ranges from a self-resolving cutaneous ulcer to a mutilating mucocutaneous disease and even to a lethal systemic illness. Cutaneous leishmaniasis often heal without rigorous treatment, however, intensive treatment is required in large and persistent lesions, or lesions over the joints or in immunocompromized patients. Therapy has long been a challenge in the more severe forms of the disease, and it is made more difficult by the emergence of drug resistance. Treatment is tailored to the individual because leishmaniasis is caused by many species or subspecies of Leishmania. Pharmacologic therapies include the following: (1) Pentavalent antimony (sodium stibogluconate or meglumine antimonate): Still the standard therapy in spite of large toxicity profile; (2) Liposomal amphotericin B (AmBisome): Effective against pentavalent antimony-resistant mucocutaneous disease and visceral leishmaniasis; (3) Oral miltefosine: Approved by the FDA for visceral leishmaniasis due to L. donovani; cutaneous leishmaniasis due to L. braziliensis, L. guyanensis, and L. panamensis; and mucosal leishmaniasis due to L. braziliensis; (4) Intramuscular pentamidine: Effective against visceral leishmaniasis but associated with pancreatic damage and disease relapse; (5) Topical paromomycin: Displayed to be effective against cutaneous leishmaniasis caused by L. major and L. Mexicana; (6) Local therapies for some forms of cutaneous leishmaniasis including photodynamic therapy and cryotherapy.
